Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists

doi:10.5500/wjt.120572

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

(9)

(6)

(0)

(119)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Transplant. Sep 18, 2026; 16(3): 120572
Published online Sep 18, 2026. doi: 10.5500/wjt.120572

Table 2 Key characteristics of commonly used glucagon-like peptide-1 and glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists for weight management

Medication class	Dosing frequency	Dosage form	Average weight loss	Key considerations
Liraglutide (Saxenda^®)	Once-daily	SC	Approximately 8%	First GLP-1 RAs approved for weight management
Semaglutide (Wegovy^®)	Once-weekly, once daily	SC, tablet	Approximately 15%-17%	Highly effective for weight loss, available in oral and injectable forms
Tirzepatide (Zepbound^®)	Once-weekly	SC	Approximately 20%-22%	First-in-class dual agonist, demonstrates superior weight loss to GLP-1 RAs

GLP-1: Glucagon-like peptide-1; RA: Receptor agonists; SC: Subcutaneous injection.

Full Size Table

Citation: Elatrebi S, Abuyadek R, Abdelbar SMM, Ahmad MS, Ayyad M, Quoritem MA, Abdel Majid RO, Arafat M, Amgad A, Alnagar A. Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists. World J Transplant 2026; 16(3): 120572
URL: https://www.wjgnet.com/2220-3230/full/v16/i3/120572.htm
DOI: https://dx.doi.org/10.5500/wjt.120572

Elatrebi S, Abuyadek R, Abdelbar SMM, Ahmad MS, Ayyad M, Quoritem MA, Abdel Majid RO, Arafat M, Amgad A, Alnagar A. Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists. World J Transplant 2026; 16(3): 120572 [DOI: 10.5500/wjt.120572]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.